Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-06
2008-05-06
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S494000
Reexamination Certificate
active
07368468
ABSTRACT:
Provided are polymorphic forms of fluvastatin sodium and processes for their preparation.
REFERENCES:
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4739073 (1988-04-01), Kathawala
patent: 5003080 (1991-03-01), Butler et al.
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5189164 (1993-02-01), Kapa et al.
patent: 5202029 (1993-04-01), Haytko et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5354772 (1994-10-01), Kathawala
patent: 5856336 (1999-01-01), Fujikawa et al.
patent: 6124340 (2000-09-01), Horvath
patent: 6696479 (2004-02-01), Van Der Schaaf et al.
patent: 2005/0032884 (2005-02-01), Lifshitz-Liron et al.
patent: 2005/0038114 (2005-02-01), Lifshitz-Liron et al.
patent: 0 363 934 (1990-04-01), None
patent: WO 00/53566 (2000-09-01), None
patent: WO 02/36563 (2002-05-01), None
patent: WO 03/004455 (2003-01-01), None
patent: WO 03/013512 (2003-02-01), None
Brittain, polymorphism in Pharmaceutical Solids, Drugs and the Pharmaceutical Science; 1999, V. 95, pp. 348-361.
Bhaskar, et al., “Enantioselective Synthesis Of Beta Hydroxy Delta Lactones: A New Approach To The Synthetic Congeners Of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors”,J. Org. Chem., 1991, pp. 5752-5754, vol. 56, No. 20.
Evans, et al., “Reduction of Beta Hydroxy Ketones With Catecholborane. A Stereoselective Approach To The Synthesis Of Syn 1,3-Diols”,J. Org. Chem., 1990, p. 5190-5192.
Lundberg, ed., “The Lipid Research Clinics Coronary Primary Prevention Trial Results: 1. Reduction In Incidence Of Coronary Heart Disease”,J.A.M.A., 1984, pp. 351-374, vol. 251, No. 3.
Scandinavian Sirnvastatin Survival Study Group, “Randomised Trial Of Cholesterol Lowering In 4444 Patients With Coronary Heart Disease: The Scandinavian Survival Study (4s)”,The Lancet, 1994, pp. 1383-1389, vol. 344.
Shao, et al., “Asymmetric Hydrogenation Of 3,5-Dioxoesters Catalyzed By Ru-Binap Complex: A Short Step Asymmetric Synthesis Of 6-Substituted 5,6-Dihydro-2-Pyronse”,Tetrahedron, 1993, pp. 1997-2010, vol. 49, No. 10.
Tang, et al., Synthesis Of Carbon-14 Labeled Fluvastatin (Lescol®),Journal of Labeled Compounds&Radiopharmaceuticals, 1998, pp. 1-7, vol. XLI, No. 1.
Tempkin, et al., “Asymmetric Synthesis of 3,5-Dihydroxy-6(E)-Heptenoate-Containing HMG-CoA Reductase Inhibitors”,Tetrahedron, 1997, pp. 10659-10670, vol. 53, No. 31.
Witztum, “Chapter 36: Drugs Used In The Treatment Of Hyperlipoproteinemias”,Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., 1996, pp. 875-897.
Aronhime Judith
Koltai Tamas
Lifshitz-Liron Revital
Perlman Nurit
Kenyon & Kenyon LLP
Saeed Kamal A.
Shiao Rei-tsang
Teva Pharmaceutical Industries Ltd.
LandOfFree
Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2782258